Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. reported a leadership change in its finance function. Effective June 6, 2026, Alan Weichselbaum will no longer serve as Chief Financial Officer, with the company stating his departure is not due to any disagreement over operations, policies, or practices. On June 3, 2026, the board appointed Andriy Mushak, a Massachusetts-licensed CPA with over 20 years of SEC reporting and audit experience, as fractional Chief Financial Officer. Mushak will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will receive $6,000 per month. The company notes he has no disclosable related-party relationships or transactions with current executives or directors.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Fractional CFO fee: $6,000 per month
1 metrics
Fractional CFO fee
$6,000 per month
Consulting compensation for Andriy Mushak as fractional CFO
Key Terms
fractional Chief Financial Officer, Consulting Agreement, emerging growth company, Item 404(a) of Regulation S-K
4 terms
fractional Chief Financial Officer financial
"appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer"
Consulting Agreement financial
"providing his services pursuant to the Consulting Agreement between the Company and LMAM"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive change did Telomir Pharmaceuticals (TELO) disclose in this 8-K?
Telomir Pharmaceuticals disclosed that Alan Weichselbaum will cease serving as Chief Financial Officer on June 6, 2026. The board appointed Andriy Mushak as fractional CFO, providing continuity in the company’s finance leadership role through a consulting arrangement.
Why did Telomir Pharmaceuticals say its CFO, Alan Weichselbaum, is leaving?
The company stated that Alan Weichselbaum’s departure as Chief Financial Officer was not due to any disagreement regarding its operations, policies, or practices. This language aims to reassure investors that the change is not tied to internal disputes or accounting concerns.
Who is Andriy Mushak, the new fractional CFO of Telomir Pharmaceuticals (TELO)?
Andriy Mushak is a Certified Public Accountant licensed in Massachusetts with over 20 years of SEC reporting and audit experience. He is a partner at LMAM Consulting Group, leading SEC reporting, financial statement preparation, and advisory services for public and private companies.
How will Telomir Pharmaceuticals compensate its new fractional CFO Andriy Mushak?
Telomir Pharmaceuticals will pay Andriy Mushak $6,000 per month for his services as fractional Chief Financial Officer. He will provide these services through LMAM Consulting Group under a consulting agreement between the company and that professional services firm.